You're invited

Angela Luttick

360biolabs

Angela Luttick is Executive Vice President, Commercial at 360biolabs, a BioAgilytix company.

Co-founder and Executive Director, Angela leads business development and future expansion activities for 360biolabs. Angela has extensive drug discovery pharmaceutical experience and expertise in early phase drug discovery through to IND filing. With a background in virology and the combination of technical expertise and business acumen, Angela understands a client's requirements from the initial engagement.

Stewart Walker

Nucleus Network

Stewart Walker is based in San Francisco, and he has worked with US biotech companies exploring the benefits of doing clinical trials in Australia for over 7 years.

James Dietrich

Acclime

James is Head of Business Development UK & Europe for Acclime following 10+ years working in International Business Development. Across his career James has worked in multiple sectors including FinTech, Sports Marketing and Recruitment. With a focus on International Business Development, James has great knowledge in helping businesses navigate international expansion.

James joined Acclime to help it continue its rapid growth in helping UK & European businesses access the APAC region. With over 8000 clients globally, Acclime has established itself as a global leader in international professional services.

During his time at Acclime, James has worked extensively within the Life Science sector attending global industry events and speaking to the benefits of the Australian R&D incentive.

Susan Szambelan

An Eye For Detail Consultancy, LLC

Clinical Operations Consultant.

With over 25 years of experience in clinical operations, Susan has led global Phase I-IV clinical studies in healthy volunteers as well as in patients (pediatric and adults) at a variety of leading biotechnology companies. She has supported several emerging companies and managed their Phase 1 First-in-Human, Drug Drug Interaction, Renal/Hepatic Impairment and ADME studies.

Susan has extensive experience in Rare Disease and Cardiovascular therapeutic areas as well as Oncology, CNS, Gout and Dermatology.

She has had an integral role in an FDA inspection and participated in several inspection readiness initiatives drawing from her knowledge of ICH GCP Guidelines.